NKTR Nektar Therapeutics
Market Cap
580.78M
Day’s Range
52W Range
Volume (3M)
1.66M
Price-Earnings Ratio
-
Revenue
95.04M
Nektar Therapeutics Latest News



About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company with operations primarily within the US and India. It researches and develops drug candidates for auto-immune diseases and cancer. Founded in 1990, Nektar Therapeutics has headquarters in San Francisco, California. It is listed under the NKTR ticker on the NASDAQ GS stock market. Easily follow the NKTR stock by making it an entry on your eToro watchlist.
Show More740
Employees
San Francisco, California, US
HQ
1990
Founded
Howard W. Robin
CEO
Upcoming Earnings
27
FEB
REPORTS
Nektar Therapeutics Q4 2022 earnings report is expected to be released after market open
Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
45
Low
Industry
Avg. 47
35
Environment
52
Social
45
Governance
People Also Bought
- AYRO AYRO Inc 5.95%
- PHUN Phunware Inc -3.60%
- QLGN Qualigen Therapeutics Inc -1.77%
- TTNP Titan Pharmaceuticals Inc 0.45%
- WATT Energous Corp -2.02%
AKA.US a.k.a. Brands Holding 3.97%
IVVD Invivyd Inc -7.89%
- ICLK iClick Interactive Asia Group ADR -1.52%